AI Engines For more Details: Perplexity Kagi Labs You
Vasodilation: Suloctidil acts by dilating blood vessels, particularly the arteries and arterioles, which leads to increased blood flow to the affected areas. This vasodilatory effect helps improve blood circulation, especially in the peripheral vascular system.
Peripheral Vascular Diseases: Suloctidil is primarily indicated for the treatment of peripheral vascular diseases, including peripheral arterial disease (PAD) and intermittent claudication. These conditions involve narrowing or blockage of the arteries that supply blood to the limbs, leading to symptoms such as leg pain, cramping, and difficulty walking.
Symptomatic Relief: By improving blood flow to the affected limbs, suloctidil can help alleviate symptoms associated with peripheral vascular diseases, such as leg pain and cramping. It may also improve exercise tolerance and walking distance in individuals with intermittent claudication.
Mode of Action: The exact mechanism of action of suloctidil is not fully understood. However, it is believed to exert its vasodilatory effects by acting as a calcium channel blocker and inhibiting the influx of calcium ions into vascular smooth muscle cells, leading to relaxation of the arterial walls.
Dosage Forms: Suloctidil is typically available in oral tablet form, with different strengths depending on the formulation and manufacturer.
Dosing: The dosage of suloctidil may vary depending on the severity of the peripheral vascular disease and individual patient response. It is usually taken orally, either with or without food, as directed by a healthcare professional.
Side Effects: Common side effects of suloctidil may include flushing, headache, dizziness, nausea, vomiting, and gastrointestinal disturbances. These side effects are usually mild and transient, but if they persist or worsen, medical attention may be required.
Contraindications: Suloctidil is contraindicated in individuals with known hypersensitivity to the drug or its components. It should also be used with caution in patients with severe hepatic impairment or renal impairment, as dosage adjustments may be necessary.
Drug Interactions: Suloctidil may interact with certain medications, including other vasodilators, antihypertensive agents, and drugs that affect liver function or metabolism. Patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking before starting suloctidil therapy.
Monitoring: Patients prescribed suloctidil should be closely monitored for therapeutic response and potential adverse effects. Regular follow-up appointments with a healthcare provider may be necessary to adjust the dosage and assess treatment effectiveness.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.6 | 0.9 | -0.5 |
| ADHD | 3.1 | 0.9 | 2.44 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.4 | 1.7 | 1 |
| Allergies | 7.3 | 2.9 | 1.52 |
| Allergy to milk products | 1.2 | 1.6 | -0.33 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 5.3 | 7 | -0.32 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.9 | 0.1 | 28 |
| Ankylosing spondylitis | 3.8 | 1.2 | 2.17 |
| Anorexia Nervosa | 1.3 | 2.6 | -1 |
| Antiphospholipid syndrome (APS) | 1.6 | 0.3 | 4.33 |
| Asthma | 4.3 | 1.7 | 1.53 |
| Atherosclerosis | 1.2 | 2.1 | -0.75 |
| Atrial fibrillation | 3.4 | 3.1 | 0.1 |
| Autism | 9.7 | 8 | 0.21 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.9 | 1.9 | |
| Bipolar Disorder | 2.1 | 1.4 | 0.5 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Breast Cancer | 0.7 | 0.7 | |
| Cancer (General) | 0.6 | 1.8 | -2 |
| Carcinoma | 4 | 2.3 | 0.74 |
| Celiac Disease | 2.6 | 3.3 | -0.27 |
| Cerebral Palsy | 1.4 | 1 | 0.4 |
| Chronic Fatigue Syndrome | 3.5 | 5.7 | -0.63 |
| Chronic Kidney Disease | 4.5 | 2.9 | 0.55 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.7 | 1.7 | 0 |
| Chronic Urticaria (Hives) | 1.5 | 0.9 | 0.67 |
| Coagulation / Micro clot triggering bacteria | 1.4 | 1 | 0.4 |
| Cognitive Function | 3.3 | 1.6 | 1.06 |
| Colorectal Cancer | 7 | 2.3 | 2.04 |
| Constipation | 1.7 | 1.3 | 0.31 |
| Coronary artery disease | 2.2 | 2.7 | -0.23 |
| COVID-19 | 7 | 9.4 | -0.34 |
| Crohn's Disease | 6.8 | 4.9 | 0.39 |
| Cushing's Syndrome (hypercortisolism) | 0.8 | -0.8 | |
| cystic fibrosis | 0.7 | 1.3 | -0.86 |
| d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
| deep vein thrombosis | 1.9 | 1.1 | 0.73 |
| Denture Wearers Oral Shifts | 1 | 1 | |
| Depression | 8.6 | 8.9 | -0.03 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2 | 1.7 | 0.18 |
| Endometriosis | 3 | 1.8 | 0.67 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 2.6 | 1.2 | 1.17 |
| erectile dysfunction | 1.7 | 0.3 | 4.67 |
| Fibromyalgia | 2.5 | 2.2 | 0.14 |
| Functional constipation / chronic idiopathic constipation | 4.9 | 3.7 | 0.32 |
| gallstone disease (gsd) | 3.2 | 0.8 | 3 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.1 | 1.2 | -0.09 |
| Generalized anxiety disorder | 2.6 | 2.4 | 0.08 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.9 | 0.8 | 0.13 |
| Graves' disease | 1.6 | 3 | -0.88 |
| Gulf War Syndrome | 0.9 | 1.1 | -0.22 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 3 | 1.8 | 0.67 |
| Heart Failure | 4 | 1.6 | 1.5 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1.2 | 0.3 | 3 |
| hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | |
| hyperglycemia | 1.4 | 1.1 | 0.27 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 3.8 | 4.9 | -0.29 |
| Hypothyroidism | 1 | -1 | |
| Hypoxia | 2.9 | 0.9 | 2.22 |
| IgA nephropathy (IgAN) | 1.3 | 4.6 | -2.54 |
| Inflammatory Bowel Disease | 6.9 | 7.6 | -0.1 |
| Insomnia | 2 | 2.1 | -0.05 |
| Intelligence | 1.1 | 0.6 | 0.83 |
| Intracranial aneurysms | 0.9 | 0.9 | 0 |
| Irritable Bowel Syndrome | 6.6 | 3.9 | 0.69 |
| ischemic stroke | 2.3 | 1.7 | 0.35 |
| Liver Cirrhosis | 6.8 | 3.2 | 1.13 |
| Long COVID | 6.7 | 6.8 | -0.01 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.9 | 0.7 | 0.29 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.6 | 0.5 |
| ME/CFS with IBS | 1.1 | 2.4 | -1.18 |
| ME/CFS without IBS | 1.5 | 1.8 | -0.2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.7 | 0.5 | 0.4 |
| Metabolic Syndrome | 6.9 | 6.3 | 0.1 |
| Mood Disorders | 8.3 | 7.4 | 0.12 |
| multiple chemical sensitivity [MCS] | 0.7 | 0.1 | 6 |
| Multiple Sclerosis | 5.9 | 5.5 | 0.07 |
| Multiple system atrophy (MSA) | 1.2 | 0.4 | 2 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 2.7 | -8 |
| Neuropathy (all types) | 0.7 | 2.4 | -2.43 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.3 | 3.8 | 0.13 |
| NonCeliac Gluten Sensitivity | 1.3 | 0.6 | 1.17 |
| Obesity | 9.1 | 6.3 | 0.44 |
| obsessive-compulsive disorder | 4.5 | 4.3 | 0.05 |
| Osteoarthritis | 2.3 | 0.9 | 1.56 |
| Osteoporosis | 2.8 | 1.6 | 0.75 |
| pancreatic cancer | 1.5 | 0.6 | 1.5 |
| Parkinson's Disease | 7 | 6.8 | 0.03 |
| Polycystic ovary syndrome | 5.1 | 2.3 | 1.22 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1 | 0.2 |
| Primary sclerosing cholangitis | 2.7 | 2.3 | 0.17 |
| Psoriasis | 2.8 | 2.8 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7.5 | 4 | 0.88 |
| Rosacea | 0.9 | 1 | -0.11 |
| Schizophrenia | 5.9 | 2.8 | 1.11 |
| scoliosis | 0.4 | 0.9 | -1.25 |
| Sjögren syndrome | 3.3 | 2.2 | 0.5 |
| Sleep Apnea | 1.6 | 1.5 | 0.07 |
| Slow gastric motility / Gastroparesis | 0.7 | 0.3 | 1.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.5 | 0.5 | 2 |
| Stress / posttraumatic stress disorder | 2.4 | 2.3 | 0.04 |
| Systemic Lupus Erythematosus | 4.2 | 2.1 | 1 |
| Tic Disorder | 1.1 | 1.8 | -0.64 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 3.7 | 3.2 | 0.16 |
| Type 2 Diabetes | 7.9 | 6 | 0.32 |
| Ulcerative colitis | 5.3 | 6 | -0.13 |
| Unhealthy Ageing | 5.5 | 2.4 | 1.29 |
| Vitiligo | 1.8 | 1.5 | 0.2 |
